Ainos, Inc. (AIMD)
NASDAQ: AIMD · Real-Time Price · USD
1.730
-0.070 (-3.89%)
At close: Jun 26, 2026, 4:00 PM EDT
1.734
+0.004 (0.25%)
After-hours: Jun 26, 2026, 5:30 PM EDT

Company Description

Ainos, Inc., a dual-platform company, focusing artificial intelligence–based smelltech technologies and immune therapeutics.

It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data.

The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women’s health sectors.

In addition, it develops VELDONA, a low-dose oral interferon platform for human and animal health applications, targeting rare, autoimmune, and infectious diseases.

The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.

Ainos, Inc. was incorporated in 1984 and is based in Houston, Texas. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.

Ainos, Inc.
Ainos logo
Country United States
Founded 1984
Industry Scientific & Technical Instruments
Sector Technology
Employees 41
CEO Chun-Hsien Tsai

Contact Details

Address:
3050 Post Oak Boulevard, Suite 510-T80
Houston, Texas 77056
United States
Phone 281 898 6586
Website ainos.com

Stock Details

Ticker Symbol AIMD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001014763
CUSIP Number 00902F402
ISIN Number US00902F4028
Employer ID 75-1974352
SIC Code 3577

Key Executives

Name Position
Chun-Hsien Tsai Chief Executive Officer, President and Chairman of the Board
Hsin-Liang Lee Chief Financial Officer
Chih-Heng Lu Director of Corporate Developoment

Latest SEC Filings

Date Type Title
May 13, 2026 10-Q Quarterly Report
May 13, 2026 8-K Current Report
Apr 17, 2026 SCHEDULE 13D/A Filing
Apr 17, 2026 SCHEDULE 13D/A Filing
Apr 17, 2026 SCHEDULE 13D/A Filing
Apr 15, 2026 SCHEDULE 13D/A Filing
Mar 30, 2026 10-K Annual Report
Mar 30, 2026 8-K Current Report
Feb 13, 2026 S-8 Securities to be offered to employees in employee benefit plans
Jan 30, 2026 SCHEDULE 13D/A Filing